Differential Splicing and Processing of mRNA Resulting From Pharmacological Perturbation of CLK Activity

The Takeda Pharmaceutical Company has recently developed a new drug to reduce the level of RNA processing that takes place within a cell. This project will look at the molecular effects of this drug at different doses in order to obtain an understanding of how cellular biology changes when RNA processing is suppressed with increasing intensity. Analysis undertaken during this internship will also provide BCCA | BCCRC and Takeda with detailed information regarding the activity and effectiveness of their drug. The resulting knowledge obtained will be useful in the development of future therapies that target RNA processing

Faculty Supervisor:

Sohrab Shah

Student:

Partner:

Takeda Pharmaceuticals North America Inc (Oakville, ON);BC Cancer Agency

Discipline:

Life Sciences

Sector:

Manufacturing

University:

The University of British Columbia

Program: